bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Oct 15, 2025 · CIK: 1712762
Sentiment: neutral
Topics: 8-K, filing, corporate-events
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on Oct 15th covering events from Oct 14th, including financials.
AI Summary
bioAffinity Technologies, Inc. filed an 8-K on October 15, 2025, reporting on events that occurred on October 14, 2025. The filing includes information on financial statements and exhibits, as well as other events. The company is incorporated in Delaware and its principal executive offices are located in San Antonio, Texas.
Why It Matters
This 8-K filing provides an update on significant corporate events and financial information for bioAffinity Technologies, Inc., which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on events and exhibits, with no immediate indication of significant financial distress or major strategic shifts.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- October 14, 2025 (date) — Earliest event reported
- October 15, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- San Antonio, Texas (location) — Principal executive offices
FAQ
What specific 'Other Events' are reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond stating that this item is included in the filing.
What is the significance of the 'Conformed Submission Type' being 8-K?
An 8-K filing signifies a current report required by the SEC for significant corporate events that occur between regular financial reporting periods.
What is the SIC code for bioAffinity Technologies, Inc. and what does it represent?
The SIC code is 8731, which corresponds to 'SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH'.
When is bioAffinity Technologies, Inc.'s fiscal year end?
The company's fiscal year ends on December 31st.
What is the Commission File Number for bioAffinity Technologies, Inc.?
The Commission File Number is 001-41463.
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-10-15 09:15:29
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_002.jpg (GRAPHIC) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 19KB
- 0001493152-25-018093.txt ( ) — 306KB
- biaf-20251014.xsd (EX-101.SCH) — 4KB
- biaf-20251014_def.xml (EX-101.DEF) — 26KB
- biaf-20251014_lab.xml (EX-101.LAB) — 36KB
- biaf-20251014_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 15, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-